ProCE Banner Activity

Key HIV Studies Influencing My Practice Following AIDS 2024—Drs Jürgen Rockstroh and Daniel R. Kuritzkes

Conference Coverage
Video

Hear from expert faculty as they discuss their insights on some of the most clinically relevant new data presented at AIDS 2024, covering studies on oral PrEP, ART switch strategies, and cardiovascular risk reduction among people with HIV.

Released: August 14, 2024

Expiration: August 13, 2025

Share

Faculty

Daniel R Kuritzkes

Daniel R Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jurgen Rockstroh

Jurgen Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
Department of Medicine I
University Hospital Bonn
Bonn, Germany  

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS

ProCE Banner

Faculty Disclosure

Primary Author

Daniel R Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD: consultant/advisor/speaker: AbbVie, Atea, Decoy, Gilead, GlaxoSmithKline, Janssen, Merck, Moderna, Pfizer, Shionogi, ViiV.

Jurgen Rockstroh, MD

Head of Infectious Diseases
Professor of Medicine 
Department of Medicine I
University Hospital Bonn
Bonn, Germany  

Jürgen Rockstroh, MD: consultant/advisor/speaker: AbbVie, Boehringer Ingelheim, Gilead, Janssen, Merck Sharp & Dohme; data and safety monitoring board: Berlin Cure.